Update - Licensing Lenzetto for Australia for AUD5.4m
Filed with ASX · · 2 pages · English
Earlier from Acrux
- Acrux licenses Lenzetto for Australian market for AUD5.4m
- Capital Gains Tax exemptions remain in place for Acrux
- Acrux raises $1.6 million via Share Placement
- Australian company unlocks a new era for women's health globally with an innovative delivery system for Female testosterone in women with low libido
- Acrux strategy focuses on Female Testosterone for low libido
Later from Acrux
- Investor Presentation - Female Testosterone for HSDD
- FY26 Annual Report and Appendix 4E
- Acrux has received $1.977m RDTI rebate for FY26
- FDA clears regulatory pathway for Female Testosterone MDTS
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux